2026: reflecting on the last year’s research progress and looking at what’s ahead
2025 was one of our most exciting years yet for Parkinson’s research. We saw the launch of EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, the start of recruitment for the phase 3 trial of ambroxol, the forging of new strategic partnerships, and much...
Learn more
The ASPro-PD trial is now underway
We are excited to announce that the first clinical centre for the ASPro-PD trial opened in February of this year, with the first participant enrolled earlier this month. This follows a delay to the start date due to drug reformulation issues which have now been…
Neurotrophic factors for Parkinson’s: insights from a previous workshop
In 2023, Cure Parkinson’s hosted a workshop where leading experts reviewed the potential of neurotrophic factors as a treatment for Parkinson’s disease. A commentary paper summarising the key outcomes was recently published in the Journal of Parkinson’s Disease. What are neurotrophic factors? Neurotrophic factors, or…
Exenatide-PD3 results published
The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately did not meet its primary or secondary endpoints. The full results of the Exenatide-PD3 study have…
Prioritising the most promising drugs for Parkinson’s: our new drug screening project
Cure Parkinson’s is excited to announce funding for a preclinical project that aims to test, evaluate and compare drugs that have the potential to slow Parkinson’s progression. Established by Cure Parkinson’s, in collaboration with Van Andel Institute (VAI), the International Linked Clinical Trials (iLCT) committee…
2025: research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s….